# A DIGITAL TRANSFORMATION TO MEET THE GROWING DEMAND FOR INNOVATIVE BIOLOGICS

Discover how a top 10 biotechnology company in China leveraged BIOVIA One Lab and Medidata AI to deliver on their R&D growth strategy.

About the Customer

A global Biotechnology company that is ranked in the top 10 in China in terms of R&D investment, specializing in the development and commercialization of innovative oncology treatments.

This biotechnology company is dedicated to patient-focused and science-driven research to discover and develop new therapies with the goal to become a leading pharmaceutical company in the industry. Their focus: pushing the boundaries for R&D with a state of the art research center, putting patients first during clinical trials to discover and develop innovative medicines, and the commercialization of Novel Drugs to meet the growing demand from patients in China and around the world.

Key Takeaways

A longtime Medidata customer, the company is also using Medidata Rave EDC and Rave Coder to streamline their clinical operations and improve data management.

The strong partnership continues and has now extended to the deployment of Medidata AI and BIOVIA ONE Lab.

BIOVIA ONE Lab is used to digitize, harmonize and standardize laboratories and Medidata AI will drive improvements in clinical trial strategic planning.

With ONE Lab and Medidata AI, the company enhanced the efficiency of new drug R&D, shortened the R&D and clinical trials cycles, and controlled costs.

By leveraging innovative solutions across Dassault Systèmes, the biotechnology company reshaped their ecosystem of novel drug R&D and improved clinical trial operational efficiency.

This aligns with its strategic plan to lead digital innovation in the biopharmaceutical industry, accelerate novel drug discovery and as a result, benefit patients around the world.

The Challenge

The Biotechnology company is focused on delivering on its R&D growth strategy and ambitions. Their R&D team includes biology, biologic, chemistry, translational Sciences, DMPK, a team of about 1000 scientists.

The Biotechnology company is seeking to digitally transform in order to meet the growing demand for innovative biologics from patients in China and globally. They were facing challenges in improving R&D efficiency and accelerating the clinical trial process.

The challenges in their R&D labs:

- Inefficiency due to extensive manual paperwork result in the low productive
- Team members experiencing fatigue when preparing documents for inspection
- Diversity of Standards in different labs and scattered experiment results including record, instrument data, etc.

The challenges in site-feasibility analysis for their global trials:

- They used an external source for site selection, but the data volume is insufficient to support their needs of global site selection.
- They wanted to know about sites that are unknown to them. They need to analyze and assess the feasibility of these unknown sites to boost the company's trial sites selection, trial enrollment, and study cycle times.

A Digital Transformation to Meet the Growing Demand for Innovative Biologics

The Solution

BIOVIA ONE Lab enabled the customer to:

- Connect Scientists, Resources, Processes, & Data for Improved Efficiency & Collaboration.

- Improve R&D processes across many groups

- Improve compliance and data integrity and Enhanced data reliability

- Reduced audit pressure and Eliminated redundant tasks

- Accelerated design of experiments and material preparation time

- Established a proprietary experimental database

- Enhanced capability for downstream technology transfer and business continuity

Medidata AI enabled the customer to:

- Identified High Performing Sites Using Medidata AI

- Increased precision and broader vision

- Faster patient recruitment

- Reduced time and improved quality

  - Selected 938 unknown sites based on the Medidata database to analyze and evaluate the feasibility of sites

    - *Number of sites known to the Biotechnology company: 152*

    - *Number of additional sites recommended by external source: 165*

   - *Number of new sites selected by Medidata AI: 938*

Figure 1: Results of Site-Selection for one indication

  - Promptly receive information about new sites for analysis by the feasibility team, enabling timely inclusion in their clinical studies.

    - *The Medidata AI database is updated on a weekly basis to ensure that the Biotechnology company can track site data in a timely manner and conduct data analysis promptly.*